Navigation Links
NeuroDerm Announces Enrollment in a Phase 2 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinson's Disease
Date:4/15/2013

NESS ZIONA, Israel, April 15, 2013 /PRNewswire/ --

NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its Phase IIa clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formula under development for continuous sub-cutaneous administration through a patch pump.  It is designed to provide steady levodopa blood levels in Parkinson's disease.

In previous phase I studies, ND0612 was shown to be safe and tolerable and reached steady state, clinically meaningful levodopa concentrations for the first time in man.  Furthermore, steady state levodopa concentrations were maintained in a practical manner during both day and night. The current Phase II double-blind, randomized placebo controlled study in Parkinson's disease patients will assess ND0612 for safety and tolerability as well as for levodopa and carbidopa steady state plasma levels.

"Following its success in phase I trials, ND0612 is now entering trials in patients. An important objective of this study will be to find out what steady state levodopa concentrations can be reached in patients. In healthy volunteers, ND0612 reached day and night steady state levodopa levels, the elusive holy grail of Parkinson's levodopa therapy, in a conveniently administered drug that should be available to all PD patients. Moreover, ND0612 bypasses the gastrointestinal tract and should be little influenced by intestinal absorption or oral ingestion of food or drugs. This trial marks a landmark in the development of ND0612, a novel levodopa drug that could become a breakthrough treatment option in Parkinson's Diseases."

About Parkinson's Disease

Parkinson's disease affects approximately 6M patients in the world. It is caused by decreasing dopamine signaling in the brain as dopaminergic brain cells die off. Levodopa is the "Gold Standard" therapy for Parkinson's disease and virtually all patients receive it. When administered through the oral route, however, levodopa combined with a decarboxylase inhibitor (carbidopa or benserazide) demonstrates a short clearance half-life and low bioavailability that contribute to motor complications in Parkinson's disease patients. Stable levodopa blood levels have been regarded as the "Holy Grail" of Parkinson's drug therapy, and ways to achieve this have been under investigation for several decades.

About ND0612

ND0612 is based on a proprietary sub-cutaneous levodopa/carbidopa drug formulation that bypasses the digestive tract. It continuously delivers levodopa to achieve straight-line and clinically-significant levodopa blood levels.  It also delivers subcutaneous carbidopa to improve the bioavailability of levodopa. ND0612 is being developed for administration via a subcutaneous delivery patch as a new treatment and intervention option in Parkinson's disease treatment. It should significantly improve the management of motor fluctuations even in patients under the best current standard of care with oral levodopa therapy.

About NeuroDerm

NeuroDerm is an emerging pharmaceutical company that develops therapies for the treatment of CNS diseases. NeuroDerm's technology is based on proprietary reformulations of well established oral drugs to achieve better efficacy. The company's lead products are ND0611 and ND0612, novel sub-cutaneous drug formulations for the treatment of Parkinson's disease and ND0801, a combination drug for the treatment of cognitive disorders in diseases such as ADD/ADHD, schizophrenia and Alzheimer's disease. NeuroDerm is headquartered in the Weizmann Science Park, Ness Ziona, Israel.

Contact:
Oded S. Lieberman , PhD MBA, Chairman & CEO
oded@neuroderm.com
Tel.: +972-8-946 2729; Cell: +1-617-517 6077



'/>"/>
SOURCE NeuroDerm Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Veracyte Announces Appointment of Shelly D. Guyer as Chief Financial Officer
2. Probiotic Action Announces New Insight on Why Acne is a Problem for First World Citizens and Offers Advice on Treatments
3. Vestiage Announces Key Partners for Launch of Monterey Bay Nutraceuticals Anti-Aging Wellness Products
4. Probiotic Action Announces A New Natural Alternative to Expensive and harmful Acne Treatments
5. Rigaku Announces New EDXRF Method for Elemental Analysis in Gold Processing
6. ?The MedZilla.com Employment Report for April, 2013: Unemployment Rate Drops as Obama Announces Major Bio-Tech Research Initiative
7. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
8. Vestiage Announces Filing of Disclosure Statement with Exchange
9. ChanTest Announces Their Second User Meeting: Partnerships in Drug Discovery
10. BioRestorative Therapies Announces Chairman of Its Scientific Advisory Board to Speak at Vatican
11. Probiotic Action Announces New Edible Probiotic Trend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
Breaking Biology Technology:
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... Dollar project, for the , Supply and Delivery ... IT Infrastructure , to Decatur ... Identity Management Solutions. Numerous renowned international vendors participated in the ... was selected for the most compliant and innovative solution. The ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
Breaking Biology News(10 mins):